Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV-301: Enfortumab Vedotin vs Chemotherapy in Previously Treated Advanced Urothelial Cancer
jRCT2080224027Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 4, randomised, open-label trial of enfortumab vedotin in transitional cell carcinoma (TCC), bladder cancer, Renal pelvis urothelial carcinoma (UTUC) and 2 more (2 arms), sponsored by Astellas Pharma. Started Aug 2018; status: completed.
02
Drugs
enfortumab vedotin
03
Conditions
transitional cell carcinoma (TCC)bladder cancerRenal pelvis urothelial carcinoma (UTUC)ureteral cancerurethral cancer
Beyond the preview
Go deeper on jRCT2080224027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224027.